Publication | Open Access
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
47
Citations
10
References
2011
Year
Nilotinib was well tolerated in these patients with advanced GIST. Accrual was halted due to insufficient clinical benefit. However, nilotinib may provide benefit to specific subsets of advanced GIST with exon 17 mutations.
| Year | Citations | |
|---|---|---|
Page 1
Page 1